This whale alert can help traders discover the next big trading opportunities. Whales are entities w

ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Law

Did you buy CAPR securities between December 17, 2025 and July 26, 2026? Affected CAPR Investor Summ

Bell and Brown Wealth Advisors LLC purchased a new stake in ImmunityBio, Inc. (NASDAQ: IBRX) in the

Bank of America Corp DE grew its stake in shares of ImmunityBio, Inc. (NASDAQ: IBRX) by 2.7% in the

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunothe

ImmunityBio beat Q2 earnings and revenue estimates as record Anktiva sales and continued adoption fu

ImmunityBio (IBRX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Esti

ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage biotechnology company, today annou

ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.08) per share which beat the analyst cons

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage biotechno

The Emirates Drug Establishment (EDE) in the United Arab Emirates on Thursday approved ImmunityBio I

ImmunityBio secures UAE marketing authorization for ANKTIVA across two cancer indications, expanding

The UAE authorization further expands ANKTIVA’s global regulatory footprint to 34 countries. The BCG

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated comm

ImmunityBio earns a cautious buy rating as Anktiva demonstrates strong efficacy and safety in NMIBC

ImmunityBio offers a best-in-class, approved immunotherapy, ANKTIVA, driving rapid revenue growth an

Short‑interest screens are lighting up with a tight cluster of mid‑ and large‑cap names where bearis

Lucid, Figma, SoundHound and Ondas are among the most heavily shorted stocks in the market right now

Biotech is the story at midday Friday, and it's not a pretty one for shareholders who chased the sec

ImmunityBio is pivoting from a single-product Anktiva focus to a broad immunotherapy platform, empha

ImmunityBio (IBRX) saw its shares surge in the last session with trading volume being higher than av

Jim Cramer recommended buying CAVA Group (CAVA), citing its potential and tasty, clean, and fun conc

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates ImmunityBio (NASDAQ:IBRX) with a B

ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage immunotherapy company, today annou

ImmunityBio, Inc. ((

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunothe

ImmunityBio targets the BCG shortage with new supply deals and label expansion efforts that could st

ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced preliminary res

The findings were presented at the International Society for Pharmacoeconomics and Outcomes Research

TAT Technologies Ltd (TATT) reported better-than-expected Q1 results, sending shares up 11.7%. Other

ImmunityBio shares rise after the FDA accepted ANKTIVA's sBLA for NMIBC, with Phase 2/3 data sho

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates ImmunityBio (NASDAQ:IBRX) with a B

Supplemental BLA seeks to expand the ANKTIVA label to include patients with BCG-unresponsive NMIBC w

ImmunityBio reported AUA 2026 data showing ANKTIVA plus BCG outperformed rival therapies in key blad

NAI+BCG versus Nadofaragene Results:NAI+BCG treated patients were twice as likely to achieve a compl

ImmunityBio secures exclusive U.S. rights to Japan BCG Lab's Tokyo strain of BCG, aiming to end

Five issued U.S. patents cover the combination of ImmunityBio's IL-15 receptor agonist (NAI) wit

Positive Phase III readout of National Cancer Institute-sponsored SWOG S1602 randomized clinical tri

ImmunityBio shares fall after Q1 losses misses estimates despite strong ANKTIVA sales growth and upd

ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.08) per share which missed the analyst co

ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.62) per share which missed the analyst co

ImmunityBio (IBRX) stock is surging. Read why Patrick Soon-Shiong's manufacturing updates and ne

Cross-trial analyses comparing ANKTIVA + BCG with nadofaragene firadenovec-vncg and TAR-200 provide

The Avis Budget short squeeze appears to be spreading to other stocks like Beyond Meat, Opendoor and

ImmunityBio Inc. (NASDAQ:IBRX) shares are trading higher Tuesday after it launched ANKTIVA in Saudi

ImmunityBio stock rises as Q1 revenue jumps 168% and Anktiva adoption grows, even as FDA warning pro

ImmunityBio responds to FDA warning on Anktiva promotions, while NCCN update and rising sales suppor

Company initiated a comprehensive review of promotional materials and is implementing enhanced adver